Onegene

About

Onegene specializes in the development of multi-targeting drugs, particularly focusing on complex diseases such as liver fibrosis and cancer. They utilize enzyme-mediated protein-protein conjugation technology known as UniStac® to create tetra-specific and tri-specific treatments. Their pipeline includes drugs like OGB21502, aimed at treating non-alcoholic steatohepatitis (NASH), and OGB23501, designed for immune activation in cancer therapy. The company emphasizes high production yield for multispecific drugs, indicating advanced manufacturing capabilities in biopharmaceuticals.